Musi wa11 Nyamavhuvhu, Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yakaratidza kuti kushandiswa kweInxMed kwemapiritsi eIN10018 kwakakurudzirwa kuti kushandiswe pakurapa kwechirwere chepfungwa, chakagadzirirwa kusanganiswa neD-1553 kurapa kenza yeKRAS G12C mutation-positive colorectal cancer (CRC) yakamborapwa kaviri kare.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Nhamba yeWeChat: 17801183037
Email：myimmnet@163.com
Nezve Ifebemtinib (IN10018)
Ifebemtinib (IN10018) mushonga unosarudza zvakanyanya, unopihwa nemuromo, uye unodzivirira FAK, une hukama hwakakosha nenzira dzakasiyana-siyana dzekurapa. Mukurapa, yakaratidza hukama hwekurapa ne chemotherapy, mishonga yakanangwa, uye immunotherapy. Kusvika pari zvino, varwere vanopfuura mazana matanhatu vakarapwa zvine hutano hwakanaka uye zvinoshivirira.
PaMusangano weGore negore weASCO wa2025, vakaburitsa ruzivo rwekiriniki rwazvino kubva mukuyedzwa kwekiriniki kwePhase Ib/II (NCT06166836; NCT05379946) kuti vaongorore kushanda uye kuchengetedzeka kweibemtinib (IN10018), mushonga unodzivirira kunamatira mumuromo (FAK) pamwe chete negarsorasib (D-1533), mushonga unodzivirira kumera mumuromo weKRAS G12C, muKRAS G12C mutant solid tumors.
Ruzivo rwekiriniki rwakaburitswa paMusangano weGore weASCO wa2025 (Chidimbu #8629 | Poster Board #109) rwaisanganisira zvakabuda mumapoka maviri:
Ruzivo rwekutevera runogara kwenguva refu rweboka revarwere veKRAS G12C-mutant non-small cell lung cancer (NSCLC) mumutsara wekutanga, pasinei nePD-L1 expression, vakagamuchira mushonga weibemtinib + garsorasib.
Boka revanhu vakamborapwa kenza yemudumbu inonzi KRAS G12C-mutant colorectal cancer (CRC) vachienzanisa inebemtinib+ garsorasib neGarsorasib monotherapy.
Muboka reNSCLC, musanganiswa weibemtinib negarsorasib, senzira yekurapa inonwiwa kaviri, isina chemotherapy, yakaratidza kubatsira kwakanyanya mukurapa kusanganisira kupindura kwakanyanya uye kushanda kwenguva refu, zvisinei nekutaura kwePD-L1, uye muboka reCRC, mhedzisiro yakaratidza kushanda kwakajeka kweibemtinib zvichienzaniswa neKRAS inhibitor monotherapy.
Zvinhu Zvikuru MuFirst-line NSCLC: Dual-Oral Regimen Inoratidza Kushanda Kwakasimba uye Kubatsirwa Kwekurarama Kunobudirira
Kubva musi wa31 Kurume, 2025, varwere veNSCLC vekutanga makumi matatu nevatatu, pasinei nekubuda kwePD-L1, vakanyoreswa uye vakagamuchira musanganiswa weibemtinib negarsorasib, neavhareji yekutevera kwemwedzi gumi nematanhatu. Kare kambani iyi yakashuma Objective Response rate (ORR) ye90.3% (data rakapihwa paESMO 2024). Data rekutevera ikozvino rakapfupikiswa seizvi:
Kurarama kwepakati pasina kufambira mberi (mPFS): mwedzi 22.3
Nguva yepakati yemhinduro DOR (mDOR): mwedzi 19.4
Kurarama kwepakati (mOS): hakusati kwasvika, nekukura kwakasimba uye kutetepa kwehupenyu zvichiratidza kubatsira kwenguva refu.
Zvakakosha kuziva kuti kurapwa uku kwakaratidza kushanda zvakanaka nguva dzose pasinei nekuti PD-L1 yakamira sei.
Zvakawanikwa Zvikuru muCRC Yakamborapwa: Kuedzwa Kwakarongwa Kunosimbisa Kubatana neKRAS G12Ci
Kubva musi wa21 Kubvumbi, 2025, varwere makumi matatu nevatanhatu vakamborapwa CRC vakangosarudzwa kuti vawane musanganiswa weibemtinib + garsorasib kana garsorasib chete. Varwere vese vakaongororwa neradiology uye mhinduro dzekudzivirira bundu dzakaongororwa uye dzakapfupikiswa seizvi:
ORR: 44.4% (yakasanganiswa) vs. 16.7% (imwe chete)
Mwero wekudzora chirwere (DCR): 100.0% (combo) vs. 77.8% (mono)
mPFS: mwedzi 7.7 (yakasanganiswa) zvichienzaniswa nemwedzi 4.0 (mwedzi mumwe chete)
mOS: haisati yasvika paruoko rwakasanganiswa; kupatsanurwa kwekutanga kunoonekwa mumakori ekurarama
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Nhamba yeWeChat: 17801183037
Email：myimmnet@163.com
Nguva yekutumira: Nyamavhuvhu-13-2025